arYla® is Slonomics applied to antibodies, a novel antibody optimization platform providing high quality, ratio-controlled combinatorial libraries. arYla offers an individualized maturation solution for antibodies. With the arYla technology, MorphoSys combines more than 15 years of experience in design and selection of therapeutic antibodies with the unique library synthesis capabilities acquired with Sloning in October 2010.
arYla brings significant advantages to antibody optimization especially in terms of speed and flexibility. The new technology enables individualized antibody libraries to be made with unprecedented speed and precision. The arYla technology uses a unique DNA engineering platform (Slonomics®) to precisely introduce the desired mutations through the production of high quality, genetically diverse, customized variant libraries of the existing compound. arYla will be used to make diverse, customized sub-libraries based on an existing lead compound, incorporating many millions of pre-defined variations at precisely determined sites within the antibody structure. In this way, antibodies optimized for a multitude of properties, including affinity, specificity, humanness, solubility, stability, production yield and others, can rapidly be identified.
The arYla Process